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Some tumors show a surprisingly tight dependence on the con-
tinued activity of a specific oncogene, even in the presence of
additional tumorigenic lesions. This is best illustrated in chronic
myeloid leukemia in man, where imatinib mesylate (Gleevec)
can cause complete regression of advanced tumors, already
refractory to regular cytotoxic drugs, by specifically inhibiting
the tyrosine kinase activity of the overexpressed BCR-ABL
oncoprotein. The dependence of this tumor on expression of
BCR-ABL is most convincingly illustrated by the observation
that in recurrent disease, the BCR-ABL often has undergone
point mutations that make the kinase refractory to the drug
(Shah and Sawyers, 2003).The obvious strategy then is to treat
CML with multiple drugs that inhibit the different conformational
variants of the BCR-ABL oncoprotein. In the case of imatinib
treatment, there are very few side effects, indicating that inhibi-
tion of physiological levels of ABL in normal cells does not
severely affect their functionality. Therefore, only the tumor is
addicted to high expression of ABL, and cannot survive without
it.This “addiction,” likely fostered by collaborating mutations pre-
sent in the tumor cells, provides an unanticipated enhancement
of the therapeutic index of the drug. One wonders whether this
principle might be also valid in other settings.
A number of conditional mouse models have been recently
described that address this oncogene addiction paradigm
(Weinstein, 2002). Most revealing are the models that activate
the same oncogene in a range of different tissues. We will focus
in this minireview on conditional Myc models, as they constitute
an intriguing set to compare (Table 1). Induction of the Myc
oncogene in the suprabasal layer of skin resulted in massive
hyperplasia and papillomatosis with extensive angiogenesis in
the dermis. Complete regression ensues after downregulation
of Myc (Pelengaris et al., 1999). Interestingly, Myc overexpres-
sion appeared to suffice to drive this complex process of papil-
lomatosis without the apparent requirement for complementing
mutations. Although this situation is rather artificial, as all
suprabasal cells are forced to express high levels of Myc and
therefore might escape from the growth-suppressive signals of
normal neighboring cells, it is remarkable that Myc overexpres-
sion alone can catalyze such complex processes. The skin
appears to respond to Myc without a requirement for additional
complementing mutations that suppress apoptosis, a genetic
alteration many cell types need to tolerate overexpression of
Myc. The tight dependence on continued expression of Myc is
not unique for the skin tumor model. In hematopoietic tumors
induced by overexpression of Myc, a similar dependence is
seen. There, Myc downregulation results in differentiation 
and apoptosis of tumor cells and resumption of normal
hematopoiesis (Felsher and Bishop, 1999). Overexpression of
Myc in pancreatic islets, however, causes degeneration of the
islets by apoptosis. Clearly in this case, the increased sensitivi-
ty to apoptosis conferred by Myc prevails over its proliferative
effect with the net result of pancreatic β cell ablation. When Myc
expression is induced in islets that overexpress the antiapoptot-
ic BclXL oncogene, the apoptotic effect of Myc is rescued, and
massive invasive tumors ensue (Pelengaris et al., 2002).
Interestingly, downregulation of Myc reverses this condition to
normal, emphasizing the dominance and dependence of Myc
overexpression for the maintenance of this tumor. An even more
astonishing observation was recently made in Myc-induced
osteogenic sarcomas. Brief downregulation of Myc resulted in
differentiation of the cells into mature bone. Subsequent reex-
pression of Myc did not reinitiate tumor growth, but rather
caused apoptosis, indicating that these differentiated cells
could not regain tumorigenic properties (Jain et al., 2002). This
might be explained by the incapacity of differentiated cells to
dedifferentiate and reestablish tumorigenic growth. It also indi-
cates that, at least in this instance, no progenitor cells have sur-
vived that could reinitiate tumor growth. This raised the
intriguing possibility that temporary downregulation of aberrant-
ly expressed oncogenes by small molecules or RNAi inhibition
might cause long-lasting tumor regression. This perspective is
particularly attractive in view of the fact that many of the specif-
ic inhibitors of oncogenic pathways can have substantial side
effects.
Two recent Myc-based tumor models show again a different
situation. In the first model, Myc overexpression in hepatocytes
results in hepatocellular carcinomas or hepatoblastomas
(Shachaf et al., 2004). Subsequent downregulation of Myc
caused tumor regression with concomitant differentiation and
apoptosis. However, a portion of the cells survive and remain
dormant. These cells can persist for long periods and show fea-
tures of cancer stem cells (Pardal et al., 2003). The survival of
these cells apparently requires the temporary expansion con-
ferred by Myc and probably involves additional mutations that
mediate a survival advantage to these cells.This is underscored
by the presence of distinct chromosomal aberration in these
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dormant cell clones. The stem cell-like features of these cells
are reflected by their capacity to differentiate into both hepato-
cytes and biliary cells. Upon reactivation of Myc, tumorigenesis
quickly resumes. While this model confirms the critical rele-
vance of a particular oncogenic pathway (Myc in this example),
the outcome is very different from what was seen in the
osteogenic tumor model mentioned above. In this liver tumor
model, continuous suppression of Myc is necessary and suffi-
cient to permanently suppress the tumorigenic potential of the
hepatocytes.
But real life is usually not that simple. There was always the
awareness that the growth of most tumors is fostered by too
many lesions to assume that suppressing a single oncogene
will be sufficient to cause long-lasting tumor regression.
Therefore, the models described above might be the exception
rather than the rule. Both clinical practice and other mouse
tumor models testify to this. Overexpression of SV40 T-Antigen
in the mandibular gland of mice causes ductal hyperproliferation
that regresses upon termination of T-Antigen expression.
However, when cells were exposed to T-Ag for longer periods,
tumor regression did occur less efficiently, and polyploid cells
remained, indicating that long-term T-Ag expression triggers
additional mutations that by themselves can provide a condition
from which tumor progression can ensue (Ewald et al., 1996).
In the current issue of Cancer Cell, inducible overexpres-
sion of MYC has been used to question whether mammary
tumorigenesis induced by MYC shows the addiction observed
in the systems described above (Boxer et al., 2004). In this
study, tetracycline-inducible MYC expression is targeted to the
mammary gland by the mammary-specific expression of the
reverse Tet transactivator (rtTA) from the MMTV promoter.
Chronic induction of mammary gland-specific MYC expression
through administration of the tetracycline analog doxycycline
results in mammary tumorigenesis. Downregulation of MYC fol-
lowing removal of doxycyclin causes regression of a fraction of
the tumors. While in some of the tumors that only temporarily
regress upon doxycyclin withdrawal, MYC expression has
become independent on induction, others resume growth with-
out requiring high levels of MYC and therefore have become
refractory to MYC inhibition, suggesting that alternative path-
ways are triggered to compensate for the lack of Myc expres-
sion. Another subgroup of the tumors do regress, but become
Myc-independent upon repeated cycles of induction and down-
regulation of Myc. Interestingly, almost 70% of the tumors that
initially do not regress carry activating point mutations in the
Kras2 gene. Kras2 was shown previously to act as the preferred
partner of Myc in mammary tumorigenesis in an inducible Myc
mammary tumor model (D’Cruz et al., 2001). Likely, the Ras
mutations are instrumental in preventing tumor regression upon
MYC downregulation. In contrast, only 25% of the tumors that
recur upon repeated Myc induction and downregulation carry
Kras2 mutations, suggesting that in this group, other lesions are
better suited to overcome the MYC addiction. The picture that
emerges from this study is that mammary tumorigenesis has its
own rules that differ from those of the other models. In the mam-
mary tumor model, Kras2 mutations (or mutations in the path-
way) are likely needed to tolerate Myc overexpression. One
might speculate that the hyperplasia induced by Myc overex-
pression permits sufficient cell expansion to allow such comple-
menting mutations to take place. One also wonders whether
Myc acts here as an initiating mutation or rather as a prolifera-
tive stimulus that allows the occurrence of other mutations that
are actually more critical for fostering the oncogenic potential of
progenitor cells, e.g., cancer stem cells. In analogy with the dis-
tinct roles of tumor-initiating and -promoting agents in chemical
carcinogenesis, Myc might fulfill here a role of promoter rather
than initiator, meaning that Myc overexpression might only pro-
mote, in a reversible fashion, malignant transformation of cells
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Tumor development, regression, and relapse in conditional MYC tumor models
Initial
response to
Conditional Tumor Neoplastic oncogene Mechanism of Mechanism
Model system phenotype Latency progression Clonality inactivation regression Relapse of relapse Reference
INV-MycERT Tamoxifen Papilloma 3 weeks Ubiquitous ND Regression Cell cycle arrest, ND ND Pelengaris 
differentiation, et al., 1999
vascular 
degeneration
Ins-MycERT; Tamoxifen Pancreatic 6 weeks Ubiquitous ND Regression Apoptosis, ND ND Pelengaris 
RIP-Bcl-xL βcell vascular et al., 2002
carcinoma degeneration
EµSR-tTA; Tet-off T cell 1322 Stochastic Clonal Regression Cell cycle arrest, Some Myc- Felsher and 
tetO-Myc lymphoma, weeks differentiation, tumors independent Bishop, 1999; 
myeloid apoptosis Karlsson et 
leukemia al., 2003
EµSR-tTA; Tet-off Osteogenic 1322 Stochastic ND Regression Cell cycle arrest, ND ND Jain et al., 
tetO-Myc sarcoma weeks differentiation 2002
LAP-tTA; Tet-off Hepato- 12 weeks Stochastic ND Regression Differentiation, Few L- or N-Myc Beer et al., 
tetO-Myc cellular (mean) apoptosis, tumors overexpression 2004; 
carcinoma, tumor dormancy Shachaf et 
hepato- al., 2004
blastoma
MMTV-rtTA; Tet-on Mammary 22 weeks Stochastic Clonal 50% ND 100% of Myc- Boxer et al., 
tetO-Myc carcinoma (mean) complete incomplete dependent 2004; DCruz 
regression, 50% regressions and Myc- et al., 2001
incomplete and 50% of independent
regression complete 
regressions 
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that have acquired initiating mutations.This would also be in line
with the observation that in human mammary tumorigenesis,
Myc amplification constitutes a tumor progression event rather
than an initiating lesion (Robanus-Maandag et al., 2003). This
then also raises the concern that the Kras2 mutations are artifi-
cially selected because of the widespread overexpression of
Myc in otherwise normal mammary epithelial cells. Indeed,
mutations in Ras are frequently seen in this model, whereas
they are rare in mammary tumors in man.
What does this variation in responses to distinct oncogenic
lesions teach us? First of all, that the concept of oncogene
addiction, although intriguing, may have limited relevance for
the majority of tumors. Secondly, that the nature of oncogene
activation, i.e., massive overexpression to high levels in a large
cell compartment, will cause cells to undergo different selection
pressures than those occurring in spontaneous tumorigenesis.
Nevertheless, although we should keep all these limitations in
mind, the various models of oncogene inactivation point to
underlying mechanisms that likely have general validity worth
paying attention to.
The different consequences of brief or prolonged MYC inac-
tivation in different cell types appear to correlate with intrinsic
and/or acquired properties of the cells of origin (Figure 1).
Tumor cells that have the capacity to undergo terminal differen-
tiation and/or apoptosis following MYC downregulation may
respond well to even brief MYC inactivation, as is the case for
MYC-induced osteogenic sarcomas. This phenomenon of Myc
might also relate to the capacity of Myc to distort the balance
between stem cell self-renewal and differentiation leading to
depletion of the stem cell compartment, as has been observed
in the hematopoietic system (Wilson et al., 2004). On the other
hand, cells that can persist in both the presence and absence of
MYC overexpression might ultimately acquire mutations that
lead to tumor recurrence, as is the case in MYC-induced hepa-
tocellular and mammary carcinomas.The nature of the initiating
oncogene appears to be of little influence on the response of
the resulting tumors to oncogene inactivation, as relapses have
been observed in animals with fully regressed mammary
tumors induced by various Tet-regulatable oncogenes.
In both the liver model and the mam-
mary tumor model, a portion of the cells
survive Myc downregulation and show
an enhanced capacity to reinitiate tumor
growth, most likely due to distinct genetic
or epigenetic changes. Identifying these
dormant cell populations and the muta-
tions therein is key, as they might
embody the driving force for tumor relapse: a cancer stem cell
compartment refractory to many of the drugs that have been
designed to attack pathways critical for expansive growth, but
that cannot eliminate dormant, nondividing cells that have
acquired enhanced survival capacity. The question then is how
we can target these dormant cells and elicit their destruction or
differentiation. We will need to know more about the lesions crit-
ical to maintain this dormant state. Their long-term survival is
remarkable, and ultimately, we need the tools to make these
cells vulnerable to small molecule intervention. Therefore, it will
be necessary to reconstitute this condition, preferentially in
vitro, in which we now can genetically manipulate these dor-
mant cells and screen for genes that show synthetic lethality
with the mutations conferring survival of these cells.
Another lesson has to be learned from these studies. The
fact that an oncogene can induce tumors does not qualify the
oncogene as an initiating mutation, even though it is instrumen-
tal in the onset of the particular tumor.The confusion might arise
because massive overexpression of oncogenes (in this case
MYC) in a large number of cells that respond by proliferation
creates a condition that will facilitate the occurrence of addition-
al mutations. Those mutations that collaborate efficiently with
MYC in fostering tumor growth will be preferentially selected.
While such mutations might not allow survival of large tumor cell
masses upon deinduction of MYC, they might confer a selective
advantage on a stem cell compartment that has different
requirements for cell survival. Kras2 might not be the most
effective gene to confer this advantage. That would explain why
the frequency of Kras2 mutations decreases in tumors that
recur after repeated induction and deinduction of MYC. These
still-to-be-found mutations might be specifically relevant for the
maintenance of a tumor stem cell compartment.
These studies also emphasize a more general point rele-
vant for modeling cancer in mice. Even though important princi-
ples can be established by models as discussed here, it will be
important to test the validity of the conclusions in tumor models
that more closely recapitulate the ontogeny of human tumors.
This will require activation of oncogenes or inactivation of tumor
suppressor genes, known to occur in early phases of human
M I N I R E V I E W
Figure 1. Different responses to oncogene
inactivation
Tumors that develop in mouse models of onco-
gene inactivation show different responses to
oncogene downregulation. Cancer cells can
undergo differentiation or apoptosis, leading to
sustained regression. Alternatively, cells can
enter a quiescent state and resume growth
upon acquiring additional mutations. Half of the
MYC-induced mammary tumors are oncogene-
independent and show no regression upon
MYC inactivation. The capital letters A, B, C, etc.
indicate the mutations acquired. A stands for
the inducible oncogene that was deinduced in
tumor-bearing animals to determine oncogene
dependence of the ensuing tumors.
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tumor growth, in a sporadic fashion in the mouse model
(Jonkers and Berns, 2002). To achieve both sporadic and
inducible oncogene expression, one could employ retroviral
delivery of the (reverse) Tet transactivator using the RCAS-TVA
system (Pao et al., 2003). Alternatively, “latent” Tet transactiva-
tor alleles that become expressed only upon somatic recombi-
nation in vivo or Cre-inducible conditional versions may be
employed. Once spontaneously occurring collaborating muta-
tions found in the model are similar to those found in the cog-
nate human tumors, one might expect that the model can
predict some of the unique responses discussed here. These
studies also emphasize the need to base cancer treatments on
knowledge of the oncogenic lesions present in the tumor. In one
case, a short treatment resulting in permanent differentiation or
apoptosis of the tumor cells might suffice. In another case, it
might be necessary to chronically suppress a critical oncogene
on which tumorigenesis fully depends. In yet another setting, a
combination treatment might be needed that specifically elicits
a proliferative response of a tumor-prone stem cell compart-
ment that is subsequently killed according to synthetic lethal
principles.
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